ARTICLE | Company News

InSite, Pharmacia, SSP Co. Ltd. deal

December 18, 2000 8:00 AM UTC

ISV regained rights from PHA to ISV-900, a DNA test that detects mutations with prognostic and diagnostic applications in glaucoma (see BioCentury, Nov. 22, 1999). ISV plans to bring the test to market next year. The companies’ collaboration to develop glaucoma treatment Diclofenac Eye (ISV-205) is unaffected (see BioCentury, Feb. 1, 1999). ...